Browse our latest Cancer Biology articles

SOX11+ breast tumours display reactivated embryonic developmental signalling and organogenetic features and are at elevated risk of developing metastases, so may benefit from more aggressive therapies.

The temporal patterns of MAPK activity differentially regulate cell autonomous and non-cell autonomous effects of oncogene expression.

PRMT7-mediated SHANK2 methylation regulates breast cancer metastasis by activating endosomal FAK signals, and may provide potential clues for tumour metastasis treatment strategies.

Identification of PARP1 trapping as the major contributor of PARP1 inhibitor-induced innate immune response.

A biomimetic and patient-specific Glioblastoma-on-a-Chip microphysiological system provides an avenue for personalized screening of PD-1 immunotherapy and novel combinational therapies that maximize therapeutic outcomes in Glioblastoma patients.

Combined EGFR and SOS1 inhibition synergize to inhibit NSCLC spheroid growth.

HPK1 is an important immuno-oncology drug target that may induce superior anti-tumor immunity through the multiple roles HPK1 may play at multiple steps of the cancer immunity cycle.

L-mimosine and dopamine protect against cisplatin-induced oto- and nephrotoxicity in zebrafish and human cell line models.

A new zebrafish study identifies compounds that shield ears and kidneys against an anticancer drug.

The unraveling of distinct mammary tumor hierarchies in various mouse models of breast cancer emphasizes the need to account for specific cell states with potentially varying therapeutic vulnerabilities in tumors.